YEAR
- 2010.08.02 Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet. Muraoka T, Aoki K, Iwasaki T, Shinoda K, Nakamura A, Aburatani H, Mori S, Tokuyama K, Kubota N, Kadowaki T, Terauchi Y.Metab. Clin. Exp. 2011 May;60(5):617-28. doi: 10.1016/j.metabol.2010.06.008
- 2010.07.15 Sterol-regulatory-element-binding protein 2 and nuclear factor Y control human farnesyl diphosphate synthase expression and affect cell proliferation in hepatoblastoma cells. Ishimoto K, Tachibana K, Hanano I, Yamasaki D, Nakamura H, Kawai M, Urano Y, Tanaka T, Hamakubo T, Sakai J, Kodama T, Doi T.Biochem. J. 2010 Jul 15;429(2):347-57. doi: 10.1042/BJ20091511
- 2010.07.14 Quinone oxidoreductase-2-mediated prodrug cancer therapy. Middleton MR, Knox R, Cattell E, Oppermann U, Midgley R, Ali R, Auton T, Agarwal R, Anderson D, Sarker D, Judson I, Osawa T, Spanswick VJ, Davies S, Hartley JA, Kerr DJ.Sci Transl Med. 2010 Jul 14;2(40):40ra50. doi: 10.1126/scitranslmed.3000615
- 2010.07.13 Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation. Cheng J, Shah YM, Ma X, Pang X, Tanaka T, Kodama T, Krausz KW, Gonzalez FJ.J. Pharmacol. Exp. Ther. 2010 Oct;335(1):32-41. doi: 10.1124/jpet.110.170225
- 2010.07.09 Mechanisms of genomic instabilities underlying two common fragile-site-associated loci, PARK2 and DMD, in germ cell and cancer cell lines. Mitsui J, Takahashi Y, Goto J, Tomiyama H, Ishikawa S, Yoshino H, Minami N, Smith DI, Lesage S, Aburatani H, Nishino I, Brice A, Hattori N, Tsuji S.Am. J. Hum. Genet. 2010 Jul 09;87(1):75-89. doi: 10.1016/j.ajhg.2010.06.006
- 2010.06.22 Identification of chromosomal aberrations of metastatic potential in colorectal carcinoma. Yamamoto S, Midorikawa Y, Morikawa T, Nishimura Y, Sakamoto H, Ishikawa S, Akagi K, Aburatani H.Genes Chromosomes Cancer. 2010 May;49(5):487-96. doi: 10.1002/gcc.20759
- 2010.05.18 Docking study and binding free energy calculation of poly (ADP-ribose) polymerase inhibitors. Ohno K, Mitsui T, Tanida Y, Matsuura A, Fujitani H, Niimi T, Orita M.J Mol Model. 2011 Feb;17(2):383-9. doi: 10.1007/s00894-010-0728-2
- 2010.05.17 Contribution of IRF5 in B cells to the development of murine SLE-like disease through its transcriptional control of the IgG2a locus. Savitsky DA, Yanai H, Tamura T, Taniguchi T, Honda K.Proc. Natl. Acad. Sci. U.S.A. 2010 Jun 01;107(22):10154-9. doi: 10.1073/pnas.1005599107
CLOSE